Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. The current pipeline includes cardiovascular disease treatment and treatments for energy metabolism disorders. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and will bring revolutionary innovations in cardiomyocyte therapy. After more than ten years of research and development, Zensun’s product line of innovative drugs and medical instruments with short, medium, or long-term horizons for commercialization is ready to begin appearing in the global market, and Zensun will become an integrated company doing research, production, and sales.
Contact
Juli Road No. 68, Zhangjiang Hi-tech Park, Pudong, Shanghai, China
Tel: +86 21 50802627
Website: http://www.zensun.com/